IOVANCE BIOTHERAPEUTICS INC CO
Reported by UBS ASSET MANAGEMENT AMERICAS INC
Reported 5,777,344 shares, up 3,869,617 (202.8%) from the prior quarter.
Reported value 36.3%; share count 202.8% vs. the prior quarter.
Reported position value by quarter
Each bar is a Form 13-F quarter-end snapshot. It does not show trades made within the quarter.
| Date | Holding Value |
|---|---|
| 2021-09-30 | 4296437 |
| 2021-12-31 | 3399186 |
| 2022-03-31 | 3621958 |
| 2022-06-30 | 1731149 |
| 2022-09-30 | 1227878 |
| 2022-12-31 | 819014 |
| 2023-03-31 | 783124 |
| 2023-06-30 | 783124 |
| 2023-09-30 | 826562 |
| 2023-12-31 | 1462563 |
| 2024-03-31 | 2665377 |
| 2024-06-30 | 15995888 |
| 2024-09-30 | 18280846 |
| 2024-12-31 | 14117180 |
| 2025-03-31 | 19238556 |
| 2025-06-30 | 1130400 |
| 2025-09-30 | 1045465 |
| 2025-12-31 | 1282298 |
| 2026-03-31 | 1664088 |
| 2026-06-30 | 2190848 |
Quarterly position history
How this manager's reported quarter-end position changed over time.
| Quarter | Activity | Shares | Change | % of reported 13F | Reported value | Filed | Source filing |
|---|---|---|---|---|---|---|---|
| Q2 2026 | Added | 526,646 | +52,547 (11.1%) | < 0.01% | $2,190,848 | 2026-08-13 | |
| Q1 2026 | Added | 474,099 | +4,393 (0.9%) | < 0.01% | $1,664,088 | 2026-05-13 | |
| Q4 2025 | Reduced | 469,706 | -12,075 (-2.5%) | < 0.01% | $1,282,298 | 2026-02-13 | |
| Q3 2025 | Reduced | 481,781 | -175,428 (-26.7%) | < 0.01% | $1,045,465 | 2025-11-14 | |
| Q2 2025 | Reduced | 657,209 | -5,120,135 (-88.6%) | < 0.01% | $1,130,400 | 2025-08-14 | |
| Q1 2025 | Added | 5,777,344 | +3,869,617 (202.8%) | < 0.01% | $19,238,556 | 2025-05-19 | |
| Q4 2024 | Reduced | 1,907,727 | -39,115 (-2.0%) | < 0.01% | $14,117,180 | 2025-02-14 | |
| Q3 2024 | Reduced | 1,946,842 | -47,658 (-2.4%) | < 0.01% | $18,280,846 | 2024-11-14 | |
| Q2 2024 | Added | 1,994,500 | +1,814,650 (1009.0%) | < 0.01% | $15,995,888 | 2024-08-14 | |
| Q1 2024 | Reduced | 179,850 | -47 (0.0%) | < 0.01% | $2,665,377 | 2024-05-15 | |
| Q4 2023 | Reduced | 179,897 | -1,765 (-1.0%) | < 0.01% | $1,462,563 | 2024-02-14 | |
| Q3 2023 | Added | 181,662 | +53,491 (41.7%) | < 0.01% | $826,562 | 2023-11-13 | |
| Q2 2023 | Unchanged | 128,171 | 0 (0.0%) | < 0.01% | $783,124 | 2023-08-11 | |
| Q1 2023 | Unchanged | 128,171 | 0 (0.0%) | < 0.01% | $783,124 | 2023-05-15 | |
| Q4 2022 | Unchanged | 128,171 | 0 (0.0%) | < 0.01% | $819,014 | 2023-02-14 | |
| Q3 2022 | Reduced | 128,171 | -28,636 (-18.3%) | < 0.01% | $1,227,878 | 2022-11-14 | |
| Q2 2022 | Reduced | 156,807 | -60,728 (-27.9%) | < 0.01% | $1,731,149 | 2022-08-12 | |
| Q1 2022 | Added | 217,535 | +39,474 (22.2%) | < 0.01% | $3,621,958 | 2022-05-16 | |
| Q4 2021 | Added | 178,061 | +3,834 (2.2%) | < 0.01% | $3,399,186 | 2022-02-14 | |
| Q3 2021 | Reduced | 174,227 | -1,684 (-1.0%) | < 0.01% | $4,296,437 | 2021-11-15 | |
|
Five years are shown. A free account unlocks the complete reported history.
Unlock full history
|
|||||||
Who else reported the position
358 managers reported IOVANCE BIOTHERAPEUTICS INC CO for Q1 2025.
| Manager | Activity | Shares | Change | % of reported 13F | Reported value | Tenure |
|---|---|---|---|---|---|---|
| VANGUARD GROUP INC | Added | 27,777,778 | +243,438 | < 0.01% | $92,500,000 | 32 qtrs |
| MHR FUND MANAGEMENT LLC | Unchanged | 24,417,103 | 0 | 9.77% | $81,308,953 | 10 qtrs |
| BlackRock Inc | Added | 24,314,578 | +838,543 | < 0.01% | $80,967,543 | 3 qtrs |
| PERCEPTIVE ADVISORS LLC | Reduced | 12,711,788 | -9,400,478 | 1.5% | $42,330,254 | 32 qtrs |
| STATE STREET CORPORATION | Reduced | 11,041,322 | -1,207,960 | < 0.01% | $36,767,602 | 32 qtrs |
| Long Focus Capital Management LLC | Added | 9,250,055 | +4,118,055 | 1.03% | $30,802,683 | 14 qtrs |
| Hood River Capital Management LLC | Added | 9,216,040 | +224,467 | 0.52% | $30,689,413 | 8 qtrs |
| Soleus Capital Management L P | Added | 7,785,000 | +1,225,000 | 1.87% | $25,924,050 | 12 qtrs |
| GEODE CAPITAL MANAGEMENT LLC | Added | 5,968,298 | +96,878 | < 0.01% | $19,878,539 | 32 qtrs |
| UBS ASSET MANAGEMENT AMERICAS INC This report | Added | 5,777,344 | +3,869,617 | < 0.01% | $19,238,556 | 32 qtrs |
Filing details and methodology As reported
- Report period
- March 31, 2025
- Filed
- May 19, 2025
- Filing type
- 13F-HR
- Position type
- COM
Voting authority reported
- Sole
- 3,417,530
- Shared
- 0
- None
- 2,359,814
“None” means the manager reported no voting authority for those shares on non-routine matters. It does not disclose why and is not evidence of securities lending.
Form 13-F is a delayed quarter-end snapshot of disclosed long Section 13(f) securities. It can be filed up to 45 days after quarter end, excludes short positions and most non-U.S. securities, and does not reveal intra-quarter trading. For options, reported shares and value describe the underlying-share exposure; strike, expiry, premium, and written positions are not disclosed.